Vik Bajaj's startup incubator at Foresite uncloaks an immunology player with a lead TYK2 inhibitor in tow
Looking at a healthcare system made more unequal by Covid-19, Foresite Capital managing director Vik Bajaj recently kickstarted an expansive plan to launch five innovative startups to address unmet need. Just weeks after the first of those biotechs emerged from stealth, a second has now uncloaked, and it’s got immunology in its sights.
Esker Therapeutics launched Wednesday with a $70 million Series A to pursue precision immunology targets backed by Bajaj’s team at Foresite, the biotech said. Foresite footed the entire round for Esker as it continues to develop its pipeline and advance its lead compound.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.